Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2020)
Oncolytics Biotech's (ONCY) quarterly EBITDA Margin came in at 18.96% in Q3 2020, up 973.0% year-over-year from 1.77% in Q4 2019, and down 15.17% quarter-over-quarter from 16.46% in Q2 2020.
Powered by 
Analysis
Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2020) Analysis & Trends
Oncolytics Biotech (ONCY) has reported EBITDA Margin for 7 consecutive years, with 18.96% the latest figure, recorded in Q3 2020.
- On a quarterly basis, EBITDA Margin rose 973.0% year-over-year to 18.96% in Q3 2020; TTM through Sep 2020 was 18.52%, a 156.0% decrease from a year earlier, with the FY2020 full-year figure at 62.55%, changed N/A from the prior year.
- EBITDA Margin was 18.96% for Q3 2020 at Oncolytics Biotech, down from 16.46% in the prior quarter.
- Over five years, EBITDA Margin peaked at 368.32% in Q2 2016 and troughed at 765.44% in Q2 2017.
- A 5-year average of 53.63% and a median of 18.96% in 2020 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin tumbled 113376 bps in 2017 and surged 2634 bps in 2020, its largest moves.
- Over 5 years, EBITDA Margin stood at 368.32% in 2016, then tumbled by 308 bps to 765.44% in 2017, then jumped by 105 bps to 35.18% in 2018, then slumped by 182 bps to 28.69% in 2019, then jumped by 34 bps to 18.96% in 2020.
- The last three EBITDA Margin figures came in at 18.96% (Q3 2020), 16.46% (Q2 2020), and 28.69% (Q3 2019), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Oncolytics Biotech | 91.92 Mn | 91.92 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -18.96% |
| Jun 30, 2020 | -16.46% |
| Sep 30, 2019 | -28.69% |
| Jun 30, 2019 | -42.80% |
| Mar 31, 2019 | -34.75% |
| Dec 31, 2018 | 35.18% |
| Sep 30, 2018 | 20.96% |
| Jun 30, 2017 | -765.44% |
| Jun 30, 2016 | 368.32% |
| Jun 30, 2010 | -813.58% |
| Dec 31, 2009 | 52.33% |
| Sep 30, 2009 | 27.90% |
| Jun 30, 2009 | 36.17% |
| Mar 31, 2009 | 42.59% |